CA3065836A1 - Agents for cancer therapy or prophylaxis and uses therefor - Google Patents

Agents for cancer therapy or prophylaxis and uses therefor Download PDF

Info

Publication number
CA3065836A1
CA3065836A1 CA3065836A CA3065836A CA3065836A1 CA 3065836 A1 CA3065836 A1 CA 3065836A1 CA 3065836 A CA3065836 A CA 3065836A CA 3065836 A CA3065836 A CA 3065836A CA 3065836 A1 CA3065836 A1 CA 3065836A1
Authority
CA
Canada
Prior art keywords
seq
antigen
polypeptide
amino acid
rankl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065836A
Other languages
English (en)
French (fr)
Inventor
Bill DOUGALL
Michele TENG
Elizabeth AHERN
Mark Smyth
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902125A external-priority patent/AU2017902125A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of CA3065836A1 publication Critical patent/CA3065836A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3065836A 2017-06-05 2018-06-05 Agents for cancer therapy or prophylaxis and uses therefor Pending CA3065836A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902125A AU2017902125A0 (en) 2017-06-05 "Agents for cancer therapy or prophylaxis and uses therefor"
AU2017902125 2017-06-05
PCT/AU2018/050557 WO2018223182A1 (en) 2017-06-05 2018-06-05 A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor.

Publications (1)

Publication Number Publication Date
CA3065836A1 true CA3065836A1 (en) 2018-12-13

Family

ID=64565634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065836A Pending CA3065836A1 (en) 2017-06-05 2018-06-05 Agents for cancer therapy or prophylaxis and uses therefor

Country Status (7)

Country Link
US (1) US20230042913A1 (enExample)
EP (1) EP3634484A4 (enExample)
JP (1) JP2020522529A (enExample)
CN (1) CN111032085A (enExample)
AU (1) AU2018280340A1 (enExample)
CA (1) CA3065836A1 (enExample)
WO (1) WO2018223182A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｒａｎｋアンタゴニストおよびその使用
MX2021008121A (es) * 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
CN110179977A (zh) * 2019-05-22 2019-08-30 华中科技大学同济医学院附属同济医院 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂
CN114222586A (zh) * 2019-06-14 2022-03-22 斯克里普斯研究学院 免疫检查点阻断性双特异性分子
EP3999544A4 (en) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
CN110938652A (zh) * 2019-11-07 2020-03-31 浙江大学医学院附属第一医院 打靶载体及构建白喉毒素调控清除巨噬细胞的f4/80-dtr转基因小鼠的方法和应用
US12679900B2 (en) 2019-12-13 2026-07-14 Biosion Inc. Antibodies binding RANKL and uses thereof
MY202559A (en) * 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
SE544000C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein
SE544001C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody
CN111808198B (zh) * 2020-07-27 2022-06-03 广东安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
US20240254245A1 (en) * 2021-05-12 2024-08-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CN118055946A (zh) * 2021-07-28 2024-05-17 科望(苏州)生物医药科技有限公司 新型多特异性分子
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
AU2023347288A1 (en) 2022-09-23 2025-03-13 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
TW202434288A (zh) * 2022-11-16 2024-09-01 大陸商蘇州盛迪亞生物醫藥有限公司 一種含抗ｒａｎｋｌ－ｎｇｆ雙特異性抗體的醫藥組成物
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
CN120418286A (zh) 2023-01-09 2025-08-01 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
IL327059A (en) * 2023-09-11 2026-05-01 Shanghai Btd Bio Tech Co Ltd A long-acting fusion protein that is an agonist for the parathyroid hormone receptor, and its use
CN122580572A (zh) * 2024-05-28 2026-08-14 北京量觉科技有限责任公司 免疫相关不良反应生物标志物及试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN104861067A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
DE202017007720U1 (de) * 2016-05-20 2025-02-11 Christoph Karl Pharmazeutische Zusammensetzungen mit Anti-RANKL-Antikörpern, Kalzium und Vitamin D, geeignet zur Behandlung und/oder Prophylaxe von Erkrankungen des Knochenstoffwechsels und von therapiebedingten Nebenwirkungen wie Hypokalzämien
MX2019002185A (es) * 2016-08-25 2019-09-19 Ai Therapeutics Inc Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.

Also Published As

Publication number Publication date
WO2018223182A1 (en) 2018-12-13
AU2018280340A1 (en) 2019-12-19
JP2020522529A (ja) 2020-07-30
EP3634484A4 (en) 2022-01-12
US20230042913A1 (en) 2023-02-09
CN111032085A (zh) 2020-04-17
EP3634484A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
US20230042913A1 (en) A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
US11746157B2 (en) PSMA binding agents and uses thereof
TWI772275B (zh) 特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
DK3097121T3 (en) ANTIBODY MOLECULES AGAINST PD-1 AND APPLICATIONS THEREOF
US10093736B2 (en) Agents for treatment of claudin expressing cancer diseases
JP2021529556A (ja) 抗腫瘍アンタゴニスト
AU2018260505A1 (en) Antibody conjugates comprising toll-like receptor agonist and combination therapies
CN108137691A (zh) 特异性针对人类t-细胞免疫球蛋白和itim结构域（tigit）的抗体
AU2017344411A1 (en) Antibodies to MICA and MICB proteins
US20220227876A1 (en) Rank antagonists and uses thereof
WO2017040660A1 (en) Combination therapy for treatment of disease
CN116390755A (zh) 抗pd-1/cd40双特异性抗体及其用途
JP2024517986A (ja) 抗－ＣＤ３００ｃ抗体を利用した併用療法
JP2024517985A (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー
EA046641B1 (ru) Агенты, связывающиеся с psma, и виды их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260206